Literature DB >> 656120

Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment.

P C Waldmeier, A E Felner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 656120     DOI： 10.1016/0006-2952(78)90525-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN： 0006-2952            Impact factor:   5.858


× No keyword cloud information.
  6 in total

1.  Biphasic effects of selegiline on striatal dopamine: lack of effect on methamphetamine-induced dopamine depletion.

Authors:  K Grasing; R Azevedo; S Karuppan; S Ghosh
Journal:  Neurochem Res       Date:  2001-01       Impact factor: 3.996

2.  Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.

Authors:  A Churchyard; C J Mathias; P Boonkongchuen; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

3.  L-deprenyl inhibits tumor growth, reduces serum prolactin, and suppresses brain monoamine metabolism in rats with carcinogen-induced mammary tumors.

Authors:  S ThyagaRajan; S K Quadri
Journal:  Endocrine       Date:  1999-06       Impact factor: 3.633

4.  Absence of "cheese effect" during deprenyl therapy: some recent studies.

Authors:  M Sandler; V Glover; A Ashford; G M Stern
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

5.  Recent observations on the clinical pharmacology of (-)deprenyl.

Authors:  G M Stern; A J Lees; M Sandler
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

6.  Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.

Authors:  A Korn; B Wagner; E Moritz; J Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.